| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JIAC.2016.01.010 |
| P8608 | Fatcat ID | release_qp6voagitncjjjxhaoh7wdyzcm |
| P932 | PMC publication ID | 4833629 |
| P698 | PubMed publication ID | 26923259 |
| P50 | author | Yohei Doi | Q73186070 |
| P2093 | author name string | Sangeeta Sastry | |
| P2860 | cites work | Adverse events associated with intravenous fosfomycin | Q60673026 |
| Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story | Q64129476 | ||
| Influence of fosfomycin on the intestinal and pharyngeal flora of man | Q70136312 | ||
| Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin | Q70545394 | ||
| Ocular penetration kinetics of fosfomycin administered as a one-hour infusion | Q71572626 | ||
| Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces | Q72475705 | ||
| Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt | Q72613621 | ||
| Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration | Q79747998 | ||
| Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy? | Q80186662 | ||
| Fosfomycin in vitro resistance of Escherichia coli from the community | Q83633063 | ||
| Comparison of single-dose and multiple-dose antibiotics for lower urinary tract infection in pregnancy | Q84420753 | ||
| Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases | Q84561801 | ||
| Fosfomycin for multidrug treatment of Klebsiella pneumoniae carbapenemase bacteremia | Q86759801 | ||
| The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate | Q87368758 | ||
| Prevalence of the fosfomycin-resistance determinant, fosB3, in Enterococcus faecium clinical isolates from China | Q87521400 | ||
| Pharmacokinetics of fosfomycin in hemodialyzed patients | Q93571394 | ||
| Whole-Genome Sequencing of Staphylococcus haemolyticus Uncovers the Extreme Plasticity of Its Genome and the Evolution of Human-Colonizing Staphylococcal Species | Q22065446 | ||
| Extended-spectrum beta-lactamases: a clinical update | Q24534999 | ||
| Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat | Q24550671 | ||
| Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate | Q24676974 | ||
| Mechanistic diversity of fosfomycin resistance in pathogenic microorganisms | Q27642794 | ||
| International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases | Q28304595 | ||
| Experimental studies on the nephrotoxicity of amphotericin B in rats | Q28325423 | ||
| Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli | Q30451453 | ||
| Susceptibility of urinary tract bacteria to fosfomycin | Q33494283 | ||
| In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin | Q33558996 | ||
| Fosfomycin tromethamine: single-dose treatment of acute cystitis. | Q33641502 | ||
| Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany | Q33703401 | ||
| In vitro susceptibility testing procedures for fosfomycin tromethamine | Q33744499 | ||
| Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes | Q33962732 | ||
| Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26 | Q33976610 | ||
| Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. | Q34096605 | ||
| Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles | Q34123684 | ||
| The mechanism of action of fosfomycin (phosphonomycin) | Q34214482 | ||
| Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus | Q34318798 | ||
| Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections | Q34421301 | ||
| F33: A-: B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in Escherichia coli from chickens in China | Q34709726 | ||
| Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome | Q34721887 | ||
| Epidemiology of urinary tract infections: incidence, morbidity, and economic costs | Q34735081 | ||
| Fosfomycin: use beyond urinary tract and gastrointestinal infections | Q34774778 | ||
| Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy | Q34782587 | ||
| Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. | Q34906223 | ||
| The fosfomycin resistance gene fosB3 is located on a transferable, extrachromosomal circular intermediate in clinical Enterococcus faecium isolates | Q35036048 | ||
| In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates | Q35076855 | ||
| Treatment of lower urinary tract infection in pregnancy | Q43570109 | ||
| Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity | Q43805708 | ||
| The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats | Q43866011 | ||
| Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates | Q43909662 | ||
| Intravenous Fosfomycin Treatment for Carbapenem-Resistant Klebsiella pneumoniae in the United States | Q44009246 | ||
| Target site penetration of fosfomycin in critically ill patients | Q44385715 | ||
| Detection of the plasmid-encoded fosfomycin resistance gene fosA3 in Escherichia coli of food-animal origin | Q44513436 | ||
| Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB | Q44598953 | ||
| Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. | Q44686193 | ||
| Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. | Q44824183 | ||
| Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. | Q45236129 | ||
| In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon | Q45773440 | ||
| Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey | Q46193575 | ||
| Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. | Q46546571 | ||
| Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. | Q46634529 | ||
| Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey | Q48044137 | ||
| In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. | Q50723093 | ||
| In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa. | Q50792742 | ||
| Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. | Q51037149 | ||
| What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. | Q51046510 | ||
| Pharmacokinetic profile of fosfomycin trometamol. | Q51599099 | ||
| Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. | Q51752083 | ||
| Dissemination of plasmid-mediated fosfomycin resistance fosA3 among multidrug-resistant Escherichia coli from livestock and other animals. | Q54321678 | ||
| Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. | Q54460259 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Multicenter Clinical Trial | Q59531111 | ||
| Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods | Q35191584 | ||
| Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial | Q35278325 | ||
| Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults | Q35310871 | ||
| Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China | Q35867426 | ||
| Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. | Q36075930 | ||
| High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis | Q36171512 | ||
| Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. | Q36290521 | ||
| Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms | Q36364199 | ||
| Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States | Q36584908 | ||
| Isolation and Characterization of a Phosphonomycin-Resistant Mutant of Escherichia coli K-12 | Q36776831 | ||
| Fosfomycin resistance protein (FosA) is a manganese metalloglutathione transferase related to glyoxalase I and the extradiol dioxygenases | Q36855782 | ||
| Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study | Q37374128 | ||
| In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study. | Q37544647 | ||
| Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections | Q37614630 | ||
| Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. | Q37643655 | ||
| Maternal urological problems in pregnancy | Q37756312 | ||
| Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials | Q37768581 | ||
| The revival of fosfomycin | Q37938425 | ||
| What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review | Q38123590 | ||
| Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria | Q38160759 | ||
| Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. | Q38325217 | ||
| Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. | Q39475307 | ||
| Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria | Q39832506 | ||
| Periplasmic protein related to the sn-glycerol-3-phosphate transport system of Escherichia coli | Q40026496 | ||
| Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates | Q40395543 | ||
| Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics | Q41081119 | ||
| Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs | Q41169926 | ||
| Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. | Q41172930 | ||
| In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase | Q41228310 | ||
| Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities | Q41433212 | ||
| Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents | Q41452382 | ||
| Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China | Q41633267 | ||
| Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux | Q41639083 | ||
| In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development | Q42012459 | ||
| Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? | Q42242522 | ||
| Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. | Q42261308 | ||
| Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit | Q42286315 | ||
| Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans | Q42930222 | ||
| In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method. | Q42930586 | ||
| Extracellular concentrations of fosfomycin in lung tissue of septic patients | Q43130327 | ||
| Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. | Q43131134 | ||
| Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms | Q43180164 | ||
| Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli | Q43195414 | ||
| Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation | Q43289024 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 273-280 | |
| P577 | publication date | 2016-02-28 | |
| P1433 | published in | Journal of Infection and Chemotherapy | Q15756830 |
| P1476 | title | Fosfomycin: Resurgence of an old companion | |
| P478 | volume | 22 |
| Q64994043 | A Questionnaire-based Survey of Physician Perceptions of the Prevalence of Antimicrobial Resistance and Their Antibiotic Prescribing Patterns. |
| Q58609298 | A systematic review of single-dose aminoglycoside therapy for urinary tract infection: Is it time to resurrect an old strategy? |
| Q33589740 | Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia |
| Q37650512 | Characterization of Two Late-Stage Enzymes Involved in Fosfomycin Biosynthesis in Pseudomonads. |
| Q57008716 | Epistatic control of intrinsic resistance by virulence genes in Listeria |
| Q90189782 | Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics |
| Q49667957 | Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. |
| Q64949904 | Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. |
| Q48380261 | Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli. |
| Q38738509 | Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group |
| Q42650271 | High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium. |
| Q33648045 | Importance of Drug Pharmacokinetics at the Site of Action |
| Q89736543 | In vitro efficacy of vancomycin combined with fosfomycin against Vancomycin-Resistant Enterococci strains |
| Q40049542 | Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections |
| Q97568276 | Multiple Plasmid Vectors Mediate the Spread of fosA3 in Extended-Spectrum-β-Lactamase-Producing Enterobacterales Isolates from Retail Vegetables in China |
| Q33707109 | Mutations of the Transporter Proteins GlpT and UhpT Confer Fosfomycin Resistance in Staphylococcus aureus |
| Q64111827 | Oral fosfomycin for the treatment of chronic bacterial prostatitis |
| Q91789304 | Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model |
| Q40237248 | Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae |
| Q54240776 | Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients. |
| Q95270284 | Pharmacological Interventions for Bacterial Prostatitis |
| Q42016011 | Plasmids of Diverse Inc Groups Disseminate the Fosfomycin Resistance Gene fosA3 among Escherichia coli Isolates from Pigs, Chickens, and Dairy Cows in Northeast China |
| Q42374450 | Prevalence of antimicrobial resistant Escherichia coli from patients with suspected urinary tract infection in primary care, Denmark |
| Q33597407 | Prevalence of inappropriate antibiotic prescriptions after the great east Japan earthquake, 2011. |
| Q57118424 | The Infinity War: How to Cope with Carbapenem-resistant Enterobacteriaceae |
| Q58694612 | Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now? |
| Q48265561 | Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies. |
| Q40075723 | Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene |
Search more.